Rutgers Research Findings on Tumor Sequencing

As published in Jama Network, Rutgers University researchers have published results from a study suggesting that a subset of patients with solid tumors may also suffer from blood conditions that introduce additional mutations into tumor sequencing data via infiltrating hematopoietic cells—especially when matching germline sequencing data not available. Rutgers studied clinical sequencing data for 2,030 individuals with solid tumors who were tested at Rutgers between 2012 and last fall. In the process they focused on eight patients initially suspected of carrying myeloproliferative neoplasm (MPN)-associated JAK2 mutations in their solid tumors. Follow the link to read the report.

Lead Research/Investigator

Hossein Khiabanian